United States Bronchodilators Market 2025: Industry Developments, Future Growth, Share & Industry Insights

Bronchodilators market size reached US$ 23.09 Billion with rise of US$ 24.07 Billion in 2024 is expected to reach US$ 36.04 Billion by 2033, growing at a CAGR of 4.6% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Bronchodilators Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/bronchodilators-market?sg

Key Players: GlaxoSmithKline (GSK), AstraZeneca, Novartis, Boehringer Ingelheim, Teva Pharmaceuticals, Sunovion Pharmaceuticals, Viatris, Cipla and Lupin.

Industry Latest News:

✅ 09 Jul 2025 - Merck (MSD) announced agreement to acquire Verona Pharma (≈$10B) - strategic buy to add Verona's COPD inhaler Ohtuvayre (ensifentrine). Merck said the deal expands its cardio-pulmonary portfolio by adding a first-in-class inhaled COPD maintenance therapy.

✅ 24 Sep 2025 - Verona Pharma shareholders approved the proposed Merck acquisition; closing expected early October 2025 (court sanction timetable published). (Shareholders' vote and related filings were published by Verona/GlobeNewswire/SEC filings.)

✅ 07 Feb 2025 - Nuance Pharma announced regulatory approval of OhtuvayreTM (ensifentrine) in Macau SAR - first market approval for ensifentrine outside the U.S. (Approval indicated maintenance treatment of COPD in adults; companies described further Greater-China regulatory activity/plans).

✅ 12 May 2025 - UK (MHRA) approved AstraZeneca's Trixeo/Breztri Aerosphere reformulated with a next-generation, near-zero-GWP propellant (world first low-carbon pMDI variation). This is a notable product reformulation launch: same active triple therapy (budesonide/glycopyrronium/formoterol) delivered with a new low-global-warming-potential propellant; CHMP/EU reviews followed in mid-2025.

✅ 25 Jul 2025 - EMA CHMP issued a positive opinion for Trixeo/Breztri with the low-GWP propellant (moves toward EU approval/variation). (Regulators and AstraZeneca highlighted the environmental/clinical bioequivalence programme.)

✅ (Mid-2025) - Ongoing clinical / guideline activity affecting bronchodilator use (context, not a single product launch): 2025 GOLD/GUIDELINES updates and major respiratory congress presentations emphasized new/novel agents (dual PDE3/4 class ensifentrine and environmental reformulations of pMDIs) and evolving roles for bronchodilator combinations in COPD/asthma management.

✅ September 2025 - AstraZeneca updated US AIRSUPRA (albuterol/budesonide) US prescribing information to reflect BATURA Phase-IIIb results (statistically significant reduction in severe exacerbation risk vs albuterol in mild asthma).

Growth Forecast Projected:

The Global Bronchodilators Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Bronchodilators Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bronchodilators-market?sg

Key Segments:

By Drug Class - Beta 2 Adrenergic Agonists, Anticholinergics Drugs, Phosphodiesterase Inhibitors, Others

By Route of Administration - Oral, Injection, Inhalation

By Indication - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others

By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Bronchodilators producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Bronchodilators revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/bronchodilators-market?sg

FAQ's

Q1: What is the current size of the Bronchodilators Market?

A: The Bronchodilators Market stood at US$ 24.07 Billion in 2024 and is set to experience remarkable growth, reaching US$ 36.04 Billion by 2033

Q2: How fast is the Bronchodilators Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 4.6% from 2025-2033.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/bronchodilators-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.